Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma

Abstract

There has been strong interest in using neoadjuvant therapy to decrease recurrence rates and facilitate surgical resection in locally advanced renal cell carcinoma. To date, no evidence exists to support improvement in oncologic outcomes with neoadjuvant therapy. Likewise, although targeted therapies have shown efficacy in tumor downsizing, this does not often translate to downstaging. Use of presurgical therapy for the purpose of downstaging inferior vena cava tumor thrombi is currently not supported. Future studies evaluating the benefit of newer immune checkpoint inhibitors will determine if there is a larger role for neoadjuvant therapy in locally advanced renal cell carcinoma.

Keywords: Immune checkpoint inhibitor; Locally advanced; Neoadjuvant therapy; Nephrectomy; Partial nephrectomy; Renal cell carcinoma; Targeted therapy.